Overview
Overview
Goals & Strategy
Executive Management
Board of Directors
Scientific Advisory Board
Business Development
Intellectual Property
Product Pipeline
Product Pipeline
Cancer
Inflammatory Diseases
Infectious Diseases
Programs and Technologies
Programs and Technologies
APC Targeting Technology™
Therapeutic Antibody Program
Immune System Modulators
Clinical Trials
Clinical Trials
Cancer Current Trials
Investors
Investors
Investor Overview
Stock Quote
Financial Reports
Corporate Governance
Presentations
Information Requests
News & Events
News Releases
Events Calendar
Scientific Articles
Media Kit
Careers
Careers
A Great Place to Work
Benefits
Current Opportunities
News Releases
Events Calendar
Scientific Articles
Media Kit
Investor Tool Kit
E-mail Page
RSS Feeds
E-mail Alerts
IR Contacts
Financial Tear Sheet
Events Calendar
Receive E-mail Alerts
Upcoming Events & Webcasts
Celldex Therapeutics, Inc. to Discuss Topline Results of Phase 2b EMERGE Study of CDX-011 Conference Call
Wednesday, May 23, 2012
Add to Calendar
remind me
days before the event
Celldex Therapeutics Annual Meeting of Stockholders
Wednesday, June 13, 2012 9:00 a.m. ET
Description
Please refer to Proxy Statement for additional information including pre-registration requirements
Location
Roseland
, NJ
Add to Calendar
remind me
days before the event
Enter your e-mail address
Past Events & Webcasts
Celldex Therapeutics, Inc. at American Association for Cancer Research Annual Meeting
Tuesday, April 3, 2012 8:00 a.m. CT
Location
Chicago
, IL
Supporting Materials
Appropriate cross-linking is required for co-stimulatory activity of human anti-CD27 antibody in a transgenic mouse model
